Husby S, Agertoft L, Mortensen S, Pedersen S
Department of Paediatrics, Kolding Hospital, Denmark.
Arch Dis Child. 1993 Mar;68(3):352-5. doi: 10.1136/adc.68.3.352.
The aim of this prospective, randomised, double blind study was to evaluate whether nebulised local steroid treatment is effective in the treatment of croup. Thirty six infants and children (0.4-4.9 years of age) admitted to hospital with moderate to severe croup were allocated to receive either 2 mg nebulised budesonide (20 children) or saline (16 children). Disease severity was assessed by a clinical total croup score based on stridor, cough, retractions, dyspnoea, and cyanosis. In addition the overall clinical impression was evaluated (0-100). Two hours after treatment there was a significant improvement in the total croup score in the group treated with budesonide (8 to 4.5), but not in the group treated with saline (8 to 8). Furthermore, the overall clinical impression assessment score decreased significantly (50 to 25) in the group treated with budesonide, whereas it remained constant in the placebo group (60 to 62). The total croup score and overall clinical severity were significantly better in the group treated with budesonide than in the placebo group. No side effects were observed. The results indicate that nebulised budesonide can be used as a safe and effective alternative treatment in children and infants with moderate to severe croup.
这项前瞻性、随机、双盲研究的目的是评估雾化吸入局部类固醇治疗在治疗喉炎方面是否有效。36名因中度至重度喉炎入院的婴幼儿（0.4 - 4.9岁）被随机分为两组，分别接受2毫克雾化布地奈德治疗（20名儿童）或生理盐水治疗（16名儿童）。根据喘鸣、咳嗽、呼吸凹陷、呼吸困难和发绀情况，通过临床喉炎总分来评估疾病严重程度。此外，还对总体临床印象进行评估（0 - 100分）。治疗两小时后，接受布地奈德治疗的组喉炎总分有显著改善（从8分降至4.5分），而接受生理盐水治疗的组则没有改善（从8分降至8分）。此外，接受布地奈德治疗的组总体临床印象评估分数显著下降（从50分降至25分），而安慰剂组则保持不变（从60分降至62分）。接受布地奈德治疗的组喉炎总分和总体临床严重程度明显优于安慰剂组。未观察到副作用。结果表明，雾化布地奈德可作为治疗中度至重度喉炎的婴幼儿的一种安全有效的替代治疗方法。
